华绿生物 reported revenue of ¥0.69B for the period ended 2026-06-30, +39.2% year on year. Net income was ¥0.06B, a 8.0% net margin on a 15.4% gross margin. The largest revenue line is 金针菇 at 61% of the total. Free cash flow for the period was ¥0.00B.
| Item | Amount | Y/Y |
|---|---|---|
| Revenue | ¥0.69B | +39.2% |
| Gross profit | ¥0.11B | — |
| Operating income | ¥0.06B | — |
| Net income | ¥0.06B | — |
| Gross margin | 15.4% | Net margin 8.0% |
| Revenue Q/Q | -32.5% | — |
| Segment | Revenue | Share |
|---|---|---|
| 金针菇 | ¥0.42B | 61.2% |
| 真姬菇 | ¥0.16B | 23.4% |
| 其他主营业务 | ¥0.11B | 15.4% |
| Item | Amount | % of revenue |
|---|---|---|
| Cost of revenue | ¥0.59B | 84.6% |
| R&D | ¥0.01B | 1.3% |
| SG&A | ¥0.04B | 6.2% |
| Tax & other | ¥-0.00B | -0.0% |
| Item | Amount |
|---|---|
| Total assets | ¥2.60B |
| Total liabilities | ¥0.92B |
| Shareholders' equity | ¥1.68B |
| Equity / assets | 64.6% |
| Operating cash flow | ¥0.02B |
| Capital expenditure | ¥0.02B |
| Free cash flow | ¥0.00B |
| Cash conversion (OCF / net income) | 296% |
The Sankey chart shows how revenue splits into cost of revenue, R&D and SG&A, and what remains as profit — clean visuals for research decks and social posts.
博亚精工 ・ 万辰集团 ・ 立高食品 ・ 商络电子 ・ 达瑞电子 ・ 深圳瑞捷 ・ 东箭科技 ・ 华利集团 ・ 祥源新材 ・ 中红医疗 ・ 苏文电能 ・ 尤安设计
Source: Eastmoney · This page shows public filing data only, not investment advice. · Browse all companies